TY - JOUR
AU - V. Tardelli
AU - K . Y. Xu
AU - A. Bisaga
AU - F. R. Levin
AU - T. M. Fidalgo
AU - R. A. Grucza
A1 - 
AD - Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo, Brazil vitorstardelli@gmail.com.;Translational Addictions Research Lab, Centre for Addiction and Mental Health, Department of Psychiatr, University of Toronto, Toronto, Ontario, Canada.;Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.;Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York City, New York, USA.;Division of Substance Use Disorders, New York State Psychiatric Institute, New York City, New York, USA.;Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.;Department of Family and Community Medicine, Saint Louis University, St. Louis, Missouri, USA.;Department of Health and Outcomes Research, Saint Louis University, St. Louis, Missouri, USA.
AN - 37500184
BT - BMJ Ment Health
C5 - Opioids & Substance Use;Healthcare Disparities
CP - 1
DA - Jul
DO - 10.1136/bmjment-2023-300728
DP - NLM
IS - 1
JF - BMJ Ment Health
LA - eng
PY - 2023
SN - 2755-9734
ST - Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
T1 - Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
T2 - BMJ Ment Health
TI - Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
U1 - Opioids & Substance Use;Healthcare Disparities
U3 - 10.1136/bmjment-2023-300728
VL - 26
VO - 2755-9734
Y1 - 2023
ER -